CA2290502C - Traitement de la cirrhose hepatique - Google Patents

Traitement de la cirrhose hepatique Download PDF

Info

Publication number
CA2290502C
CA2290502C CA002290502A CA2290502A CA2290502C CA 2290502 C CA2290502 C CA 2290502C CA 002290502 A CA002290502 A CA 002290502A CA 2290502 A CA2290502 A CA 2290502A CA 2290502 C CA2290502 C CA 2290502C
Authority
CA
Canada
Prior art keywords
halofuginone
group
collagen
liver
hepatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002290502A
Other languages
English (en)
Other versions
CA2290502A1 (fr
Inventor
Mark Pines
Arnon Nagler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Original Assignee
Hadasit Medical Research Services and Development Co
Agricultural Research Organization of Israel Ministry of Agriculture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25338371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2290502(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hadasit Medical Research Services and Development Co, Agricultural Research Organization of Israel Ministry of Agriculture filed Critical Hadasit Medical Research Services and Development Co
Publication of CA2290502A1 publication Critical patent/CA2290502A1/fr
Application granted granted Critical
Publication of CA2290502C publication Critical patent/CA2290502C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002290502A 1997-05-23 1998-05-22 Traitement de la cirrhose hepatique Expired - Fee Related CA2290502C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86238297A 1997-05-23 1997-05-23
US08/862,382 1997-05-23
PCT/US1998/010505 WO1998052514A2 (fr) 1997-05-23 1998-05-22 Traitement de la cirrhose hepatique

Publications (2)

Publication Number Publication Date
CA2290502A1 CA2290502A1 (fr) 1998-11-26
CA2290502C true CA2290502C (fr) 2007-08-28

Family

ID=25338371

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002290502A Expired - Fee Related CA2290502C (fr) 1997-05-23 1998-05-22 Traitement de la cirrhose hepatique

Country Status (8)

Country Link
EP (1) EP1014988A2 (fr)
JP (1) JP2002515905A (fr)
KR (1) KR100540537B1 (fr)
CN (1) CN1160073C (fr)
AU (1) AU748754B2 (fr)
CA (1) CA2290502C (fr)
IL (1) IL132848A (fr)
WO (1) WO1998052514A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558261A4 (fr) * 2002-10-31 2008-06-04 Israel State Compositions de quinazolinone destinees a reguler l'expression genetique dans des processus pathologiques

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) * 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
CA2113229C (fr) * 1994-01-11 1999-04-20 Mark Pines Compositions anti-fibreuses contenant de la quinazolinone et methodes d'utilisation correspondantes

Also Published As

Publication number Publication date
KR100540537B1 (ko) 2006-01-10
CN1265034A (zh) 2000-08-30
JP2002515905A (ja) 2002-05-28
CN1160073C (zh) 2004-08-04
AU7692298A (en) 1998-12-11
IL132848A0 (en) 2001-03-19
WO1998052514A2 (fr) 1998-11-26
AU748754B2 (en) 2002-06-13
EP1014988A2 (fr) 2000-07-05
KR20010012838A (ko) 2001-02-26
WO1998052514A3 (fr) 1999-08-19
IL132848A (en) 2004-08-31
CA2290502A1 (fr) 1998-11-26

Similar Documents

Publication Publication Date Title
JP6527497B2 (ja) Ｌ−オルニチンフェニル酢酸塩を用いる門脈圧亢進の治療及び肝機能の修復
AU2006247504B2 (en) Methods and compositions for the treatment of autoimmune and inflammatory diseases associated with Toll-like receptors
US6313131B1 (en) Method of kidney treatment
EP2582683B1 (fr) Traitement de la goutte et de l'hyperuricémie
US5672622A (en) Treatment of multiple sclerosis
EP1755615B1 (fr) Traitement de soutien d'une maladie du foie
IL131348A (en) Composition for treatment and prevention of adhesions
US6562829B1 (en) Treatment of hepatic cirrhosis
JP2003531171A (ja) 高脂血症関連疾患に対する組成物および治療
CA2568436A1 (fr) Therapie combinee impliquant un antagoniste de recepteur d'adenosine a1 et un inhibiteur d'aldosterone
JP2002509540A (ja) アルドースレダクターゼ阻害剤およびａｃｅ阻害剤を含有する医薬組成物
AU2002309211B2 (en) Treatment of renal fibrosis
CA2290502C (fr) Traitement de la cirrhose hepatique
US5872124A (en) Treatment of diseases of the central nervous system using uric acid as a scavenger of peroxynitrite
AU777537B2 (en) Use of riluzole for the treatment of multiple sclerosis
AU2002309211A1 (en) Treatment of renal fibrosis
US20140288102A1 (en) Prevention of recurrences of urethral strictures following conventional therapy
AU739148B2 (en) Treatment of skin disorders
KR20010083123A (ko) 알레르기 질환 치료제
CA2285350A1 (fr) Traitement de la fibrose pulmonaire
US7179838B2 (en) Coumarin analog compounds for safer anticoagulant treatment
WO2005055997A1 (fr) Composition medicinale pour traiter et pour prevenir une maladie inflammatoire
AU2008201290B2 (en) Therapeutic treatment
JP4504465B2 (ja) 肝線維化防止剤
AU2005235436B2 (en) Supportive treatment of liver disease

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed